Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with bleeding disorders.
Approximately 90% of 67 multi-transfused patients with bleeding disorders were positive either for anti-HBs (85%) or HBsAg (45%). Using a polyethylene glycol trypsinization assay, we found anti-HbsAg-containing specific circulating immune complexes (HBsAg-CICs) in 3 of the 57 HBsAg-negative haemophiliacs possessing anti-HBs. The occurrence of HBsAg-CICs may be a regular event in the conversion phase of HBs infection. Circulating immune complexes as detected by the anticomplementary assay were found in 32 of the 67 (48%) patients.
D000410:Alanine Transaminase / Q000097:blood; D000936:Antigen-Antibody Complex; D003165:Complement System Proteins / Q000276:immunology; D006467:Hemophilia A / Q000276:immunology*; D002836:Hemophilia B / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D011092:Polyethylene Glycols / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology; D014842:von Willebrand Diseases / Q000276:immunology
D000936:Antigen-Antibody Complex; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D011092:Polyethylene Glycols; D003165:Complement System Proteins; D000410:Alanine Transaminase; D014357:Trypsin